Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C

O'Brien TR, Lang Kuhs KA, Pfeiffer RM. Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infectious Diseases. 2014;1(3):ofu110.

Publication Type:

Journal Article

Source:

Open Forum Infectious Diseases, Volume 1, Issue 3, p.ofu110 (2014)

Keywords:

clinical trial, cost-effectiveness, Direct-acting antiviral agents, gender, hepatitis C virus, IFNL4
Top